| 49.6 0.63 (1.29%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.68 | 1-year : | 73.21 |
| Resists | First : | 53.67 | Second : | 62.68 |
| Pivot price | 48.51  |
|||
| Supports | First : | 42.13 | Second : | 35 |
| MAs | MA(5) : | 50.22  |
MA(20) : | 48.04 |
| MA(100) : | 30.75 |
MA(250) : | 22.73 |
|
| MACD | MACD : | 2.9 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 54.8 |
D(3) : | 58.8 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 53.67 | Low : | 13.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CDNA ] has closed below upper band by 32.8%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.61 - 50.86 | 50.86 - 51.07 |
| Low: | 47.68 - 47.94 | 47.94 - 48.16 |
| Close: | 48.58 - 49 | 49 - 49.34 |
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Wed, 02 Sep 2026
CCORF Initiates CareDx(CDNA.US) With Buy Rating, Announces Target Price $65 - Moomoo
Fri, 28 Aug 2026
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen - ChartMill
Thu, 27 Aug 2026
CareDx (CDNA) is a Great Momentum Stock: Should You Buy? - qz.com
Thu, 20 Aug 2026
Ron Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF Value - GuruFocus
Mon, 17 Aug 2026
CareDx (NASDAQ: CDNA) insider lines up $423K stock sale - stocktitan.net
Fri, 14 Aug 2026
CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 52 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 103.4 (%) |
| Shares Short | 6,140 (K) |
| Shares Short P.Month | 8,340 (K) |
| EPS | 2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.27 |
| Profit Margin | 24.2 % |
| Operating Margin | 0.1 % |
| Return on Assets (ttm) | -0.3 % |
| Return on Equity (ttm) | 29.4 % |
| Qtrly Rev. Growth | 52.2 % |
| Gross Profit (p.s.) | 6.25 |
| Sales Per Share | 8.85 |
| EBITDA (p.s.) | 0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 94 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | 23.99 |
| PEG Ratio | 0 |
| Price to Book value | 6.03 |
| Price to Sales | 5.63 |
| Price to Cash Flow | 27.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|